Share This Page
Drug Price Trends for NDC 59651-0791
✉ Email this page to a colleague
Average Pharmacy Cost for 59651-0791
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| HALOPERIDOL 2 MG TABLET | 59651-0791-01 | 0.20152 | EACH | 2024-12-18 |
| HALOPERIDOL 2 MG TABLET | 59651-0791-01 | 0.20267 | EACH | 2024-12-04 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59651-0791
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
59651-0791 Market Analysis and Financial Projection
Market Analysis and Price Projections for Pharmaceutical Drugs: A Comprehensive Overview
Introduction
The pharmaceutical market is a complex and dynamic sector, influenced by a multitude of factors including regulatory environments, market demand, and technological advancements. This article will delve into the current trends, price projections, and key considerations for pharmaceutical drugs, with a specific focus on the broader market context rather than a specific NDC code like 59651-0791, which was not found in the provided sources.
Global Pharmaceutical Market Trends
The global pharmaceutical market has seen significant growth over the past few years, driven by increasing demand for healthcare services and the development of new, often expensive, treatments.
- Price Disparities: The United States stands out with drug prices that are substantially higher than in other regions. In 2022, the average price per unit in the U.S. was 5.5 times as high as in the OECD (excluding the U.S.) and 7.7 times as high as the rest of the world[3].
- Volume and Revenue Growth: While the volume of prescription drugs has grown globally, the U.S. has seen a disproportionate increase in sales revenues due to higher prices. Between 2017 and 2022, the U.S. saw an average price increase of 14%, whereas prices in the OECD (excluding the U.S.) and the rest of the world decreased by 9% and 7%, respectively[3].
Drug Price Inflation Projections
For 2025, several key trends and projections are noteworthy:
- Overall Inflation Rate: Vizient projects an overall drug price inflation rate of 3.81% for 2025. This estimate is based on various factors, including the expanding indications of previously approved medications and the introduction of new high-cost therapies[2][5].
- High-Cost Therapies: Gene and cell therapies are expected to significantly impact provider budgets. These therapies, which can range from $250,000 to $4.25 million per treatment, are becoming more prevalent and are anticipated to transform healthcare by potentially preventing or curing chronic diseases[2][5].
Impact of New Therapies
Gene and Cell Therapies
- These therapies are entering the market at an unprecedented pace, with close to 300 therapies currently in clinical trials. Recent approvals include treatments for inherited blood disorders and pediatric neurological conditions, highlighting the potential for transformative healthcare outcomes but also posing significant budgetary and operational challenges[2][5].
CAR-T and Bispecific T-Cell Engagers
- In the oncology sector, CAR-T therapies have grown exponentially since their introduction in 2017. Currently, there are six CAR-T agents with indications for various types of lymphoma, myeloma, and chronic lymphocytic leukemia, each priced at more than $455,000 per treatment. Bispecific T-cell engagers, a newer class of treatments, have also gained traction, with prices ranging from $9,715 to $360,500 for a full treatment course[2].
Expanding Indications for Existing Medications
- GLP-1 Agents: Medications like semaglutide (Ozempic® and Wegovy®) and tirzepatide (Mounjaro® and Zepbound®) have seen significant increases in spend due to their expanding indications. These medications are not only used for diabetes and obesity but also for reducing the risk of major adverse cardiovascular events in overweight or obese adults with established cardiovascular disease. Semaglutide, in particular, has seen a 77% increase in spend compared to the previous year[2].
Regulatory and Market Factors
- Market Demand: The demand for pharmaceuticals is driven by demographic changes, such as an aging population, and the increasing prevalence of chronic diseases. This demand, coupled with the introduction of new therapies, drives up prices[3].
- Regulatory Environments: Regulatory policies and reimbursement models significantly influence drug prices. In the U.S., the lack of price controls and the complex reimbursement landscape contribute to higher drug prices compared to other regions[1][3].
Operational and Budgetary Implications
Healthcare providers are facing significant operational and budgetary challenges due to the increasing costs of pharmaceuticals.
- Budgetary Obstacles: The introduction of high-cost therapies requires health systems to quickly identify qualified patients, access treatments, and synchronize logistics for drug administration. This necessitates cross-functional planning and a long-term approach to manage these novel therapeutics effectively[2].
- Operational Challenges: Providers must prepare for the increased administrative burden associated with managing complex and expensive treatments. This includes ensuring proper storage, handling, and administration of these therapies[2].
Key Takeaways
- The pharmaceutical market is characterized by high and increasing drug prices, particularly in the U.S.
- New therapies, such as gene and cell therapies, are transforming healthcare but pose significant budgetary and operational challenges.
- Expanding indications for existing medications, like GLP-1 agents, are driving up spend.
- Regulatory environments and market demand play crucial roles in shaping drug prices.
- Healthcare providers need to adopt a cross-functional and long-term approach to manage the introduction of high-cost therapies.
FAQs
Q: What is the projected overall drug price inflation rate for 2025? A: The projected overall drug price inflation rate for 2025 is 3.81%, according to Vizient's summer Pharmacy Market Outlook[2].
Q: Why are drug prices in the U.S. significantly higher than in other regions? A: Drug prices in the U.S. are higher due to factors such as the lack of price controls, a complex reimbursement landscape, and a drug mix that skews towards more expensive compounds[3].
Q: What are some of the new high-cost therapies entering the market? A: Gene and cell therapies, including CAR-T therapies and bispecific T-cell engagers, are among the new high-cost therapies entering the market. These therapies can range from $250,000 to $4.25 million per treatment[2].
Q: How are expanding indications for existing medications impacting the market? A: Expanding indications for medications like semaglutide and tirzepatide are driving up spend as these drugs are now used for a broader range of conditions, including cardiovascular disease prevention[2].
Q: What operational challenges do healthcare providers face with new therapies? A: Healthcare providers face challenges such as identifying qualified patients, accessing treatments, and synchronizing logistics for drug administration, which requires cross-functional planning and a long-term approach[2].
Sources
- DrugPatentWatch - Latest drug prices and trends for NDC 59630-0551[1].
- Vizient Inc. - Vizient projects drug price inflation at 3.81%[2].
- ASPE - International Market Size and Prices[3].
- FDA.report - NDC 59651-018 Oral Tablet, Extended Release Niacin[4].
- Vizient Inc. - Pharmacy Market Outlook Summer 2024[5].
More… ↓
